Clinical Trial Update: Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update describes cognitive processing speed changes in relapsing multiple sclerosis patients treated with Ozanimod (RPC-1063) and notes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ozanimod (ozanimod)

Snippet

Sponsor: Celgene | Conditions: Multiple Sclerosis | Phase 3 | Status: TERMINATED